AW-15'1129 is a drug with an imidazo-quinazoline based structure. The pharmacology is described as antidepressant based on strong adrenergic and anti-REM effects. It was invented by Othmar Dr Schindler of Wander AG in the 1960's. Although the drug is not known to have ever been commercialized, it is a representative example of a psychochemical based on a rational synthetic design.[1][2][3]
In the patent the dosage of API is formulated to a strength of 4mg per tablet.[4][5]
This is then refluxed with benzaldehyde in alcoholic acid to give 6-phenyl-2,3,6,7-tetrahydro-4H-pyrimido[1,2-c]quinazoline. Reduction with potassium borohydride gives 5-phenyl-2,3,5,6-tetrahydro-imidazo[1,2-c]quinazoline.
^Stille, G., Lauener, H., Eichenberger, E., Matussek, N., Pöldinger, W. (May 1968). "Observations concerning adrenergic functions and antidepressant activity: Pharmacological, biochemical and clinical results with a new imidazo-quinazoline derivative 1". Pharmacopsychiatry. 1 (2): 123–135. doi:10.1055/s-0028-1094213.
^B. Roth, J. Faber and S. Nevs̈imalova, Activ. Nerv. Super., 14, 35 (1972).
^Kwok, R. (August 1978). "Preparation of some tricyclic fused ring iminopyrido[3,2- e ]pyrimidines". Journal of Heterocyclic Chemistry. 15 (5): 877–880. doi:10.1002/jhet.5570150531.
This article needs additional or more specific categories. Please help out by adding categories to it so that it can be listed with similar articles.(June 2025)